Skip to content
All Sections
Subscribe Now
77°F
Wednesday, July 31st 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
77°F
Wednesday, July 31st 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Baudax Bio, Inc.
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
May 12, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio to Present at the Sidoti Virtual Investor Conference
May 03, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Closing of $4 Million Public Offering
May 01, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Pricing of $4 Million Public Offering
April 26, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
April 25, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
April 24, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
March 27, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
February 23, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
January 24, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
December 08, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Closing of $5 Million Public Offering
December 06, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Pricing of $5 Million Public Offering
December 02, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces 1-for-40 Reverse Stock Split
November 30, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
November 08, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close